Strategic Advocates’s Globus Medical GMED Stock Holding History

Strategic Advocates’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4	Closed	-$352	–	402
2025 Q4	$352	Hold	4	–	–	﹤0.01%	561
2025 Q3	$229	Buy	+4	New	+$230	﹤0.01%	558

Other funds holding GMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Strategic Advocates's GMED Position: Q1 2026 in Review

Strategic Advocates sold out of Globus Medical (GMED) in Q1 2026, closing a stake of 4 shares — an estimated $352 sold.

Strategic Advocates first reported a position in GMED in Q3 2025 and held it in 2 quarters. The position peaked at $352 in Q4 2025. 602 funds tracked by Wall St. Rank hold GMED as of Q1 2026.

Strategic Advocates reported no remaining Globus Medical position as of Q1 2026 after selling out during the quarter.
Strategic Advocates sold 4 Globus Medical shares in Q1 2026, an estimated $352.
Strategic Advocates first reported a position in Globus Medical in Q3 2025 and held it in 2 quarters.
Strategic Advocates's Globus Medical position peaked at $352 in Q4 2025.
602 funds tracked by Wall St. Rank held Globus Medical as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.